Novartis abandons effort for U.S. approval of biosimilar rituximab
Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used to treat certain cancer and rheumatoid arthritis.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Arthritis | Cancer | Cancer & Oncology | Health | Rheumatoid Arthritis | Rheumatology | Rituxan